Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

14.46 1.05

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

14.31

Max

14.72

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-4.3M -18M
Pelnas, tenkantis vienai akcijai	-0.19
Darbuotojai	37
EBITDA	-5.3M -17M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+104.01% upside

Dividendai
By Acuity
Kitas uždarbis	2026-11-03

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	130M 1.3B
Ankstesnė atidarymo kaina	13.41
Ankstesnė uždarymo kaina	14.46

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-08-21 23:56; UTC

Mettler-Toledo shares are higher in after-market trading, reflecting a broader market rebound amid gains from major stocks like Tesla and UnitedHealth.

2026-08-21 23:56; UTC

Constellation Energy shares are higher in after-market hours, reflecting broader gains among major stocks. No specific news was identified for the price movement.

2026-08-21 23:56; UTC

Virtu Financial Inc. shares are higher in after-market trading, following a broader market rebound despite earlier pressures from rising crude oil prices and bond yields.

2026-08-21 23:56; UTC

TE Connectivity Ltd. shares declined in after-market trading, remaining near the lower end of their one-month range and below the 20-day moving average.

2026-08-21 23:56; UTC

APA Corp. is trading higher in after-market hours, reflecting broader market strength despite a recent yield-driven selloff. No specific news was identified.

2026-08-21 23:56; UTC

Social Media

Options trading for Costco includes a notable $950 call option that rose from $0.99 to $2.70. Shares remain roughly flat in after-market trading.

2026-08-21 23:56; UTC

MercadoLibre Inc. is higher in after-market hours, reflecting routine performance amid broader market gains following earlier pressure from rising crude oil prices and bond yields.

2026-08-21 23:56; UTC

NiSource shares are higher in after-market trading, reflecting broader market gains following a recent selloff. No specific company news was identified.

2026-08-21 23:56; UTC

OPKO Health Inc. shares declined in after-market trading, despite gains in major stocks as the broader market rebounded from earlier pressures.

2026-08-21 23:56; UTC

Agilent Technologies Inc shares are lower in after-market hours, diverging from broader market gains. No specific news was identified to explain the decline.

2026-08-21 23:56; UTC

Devon Energy Corp shows little change in after-market trading, remaining near unchanged since Friday's close and positioned 8.63% above its 20-day moving average.

2026-08-21 23:56; UTC

Ginkgo Bioworks Holdings Inc is higher in after-market trading amid a broader market rebound, despite no specific company news identified.

2026-08-21 23:56; UTC

Equitable Holdings Inc shares are lower in after-market hours, with no specific news identified. The stock remains below its 20-day moving average.

2026-08-21 23:56; UTC

Correlated Moves

US Bancorp shares are higher in after-hours trading, reflecting positive sentiment in the banking sector amid a broader market rebound.

2026-08-21 23:56; UTC

Intellia Therapeutics shares are higher in after-market trading, reflecting a broader market rebound following a recent yield-driven selloff.

2026-08-21 23:56; UTC

Macro News

ETF Constituents

Vanguard Information Technology ETF rises in after-market hours, supported by gains in key holdings like NVIDIA, Apple, and Intuit amid broader market recovery.

2026-08-21 23:56; UTC

Century Aluminum Co. shares gained after-market, recovering from an earlier dip. The movement reflects broader market trends amid rising crude oil prices and bond yields.

2026-08-21 23:56; UTC

Correlated Moves

Duke Energy shares rose in after-market trading, reflecting broader market gains despite remaining below the 20-day moving average after four consecutive lower sessions.

2026-08-21 23:56; UTC

B&G Foods Inc. traded roughly flat during after-market hours with no specific news. The broader market rebounded, but the stock remains near its one-month low.

2026-08-21 23:52; UTC

South Africa's Balance of Trade Report on August 28, 2026: Analysts Anticipate Continued Surplus Amid Global Economic Instability.

2026-08-21 23:52; UTC

S&P/Case-Shiller Home Price Index Release on August 25, 2026, Expected to Show Modest Growth Amid Mixed Housing Market Sentiment and Rising Inflation Concerns.

2026-08-21 23:52; UTC

US GDP Price Index QoQ 2nd Estimate for Q2, forecasted at a 0.063% increase, set to release on August 26 amid rising optimism in economic indicators and inflation concerns.

2026-08-21 23:52; UTC

XRP is trading higher during Friday's session, supported by a broader cryptocurrency rally and a U.S. Treasury announcement on bond buyback operations.

2026-08-21 23:51; UTC

Shares of Science Applications International Corp. are lower in after-market trading, reflecting a notable retracement despite being above the 20-day moving average.

2026-08-21 23:51; UTC

Karyopharm Therapeutics Inc shares are lower in after-market hours, following a brief uptick earlier. No specific news was identified to explain the decline.

2026-08-21 23:51; UTC

Par Pacific Holdings Inc. shares are lower in after-market hours, continuing a trend within the broader context of its one-month trading range.

2026-08-21 23:51; UTC

Paylocity Holding Corp shares are lower in after-market trading, with no specific news identified for the decline. The stock remains above its 20-day moving average.

2026-08-21 23:51; UTC

Shift4 Payments Inc is trading higher in after-market hours, supported by a rally in cryptocurrencies that benefits crypto-exposed equities.

2026-08-21 23:51; UTC

Coca-Cola Europacific Partners PLC shares are higher in after-market hours, recovering from an earlier dip amid broader market trends and a cryptocurrency rally.

2026-08-21 23:51; UTC

Kirby Corp shares are higher in after-market trading, reflecting a strong performance that exceeds the 20-day moving average. No specific news was identified.

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

104.01% į viršų

12 mėnesių prognozė

Vidutinis 29.5 USD 104.01%

Aukščiausias 33 USD

Žemiausias 27 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.